Boston Scientific Rises Despite Mixed Earnings, Light 2022 GuidanceInvestors Business Daily • 10/26/22
Boston Scientific stock drops more than 4% after profit misses expectations but sales beat, outlook mixedMarket Watch • 10/26/22
Boston Scientific Announces Conference Call Discussing Third Quarter 2022 ResultsPRNewsWire • 10/03/22
Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL™ Cerebral Protection SystemPRNewsWire • 09/17/22
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication OptionPRNewsWire • 09/06/22
Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property LitigationsPRNewsWire • 08/01/22
Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/27/22
Boston Scientific Narrowly Tops Second-Quarter Expectations; Shares SurgeInvestors Business Daily • 07/27/22
Boston Scientific tops profit and sales expectations, but trims full-year outlookMarket Watch • 07/27/22